Azitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
Wednesday, July 15, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Azitra, Inc. has announced promising results for its ATR-COSF program, which utilizes a recombinant human protein derived from S. epidermis. The ex vivo data indicates enhanced distribution and elasticity, positioning the formulation as a valuable cosmetic ingredient. This breakthrough could lead to advancements in cosmetic applications.
Price reaction · baseline $0.1332 (2026-07-15T14:07:00.000Z) · hit during market hours · clean, no other AZTR news in the window
day 0 close · peak
+1.4%
Market Sentiment Analysis
POSITIVE FACTORS
Demonstrated increased distribution and elasticity in results.
Breakthrough results for ATR-COSF program.
Potential high value cosmetic ingredient.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
High dilution risk
Lead asset
ATR04-484
Phase 1 · EGFR Inhibitor-associated Rash
Full Press Release Details
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value cosmetic ingredient Ex vivo data successfully showed controlled distribution of the
Frequently Asked Questions
What is the ATR-COSF program?
The ATR-COSF program is in development by Azitra, utilizing a recombinant human protein for cosmetic applications.
What results were announced by Azitra?
Azitra announced breakthrough results showing increased distribution and elasticity from their ATR-COSF program.
What is rHDfilaggrin?
rHDfilaggrin is a recombinant human domain of the protein filaggrin used in the ATR-COSF formulation.
What is the source of the supernatant in ATR-COSF?
The supernatant used in ATR-COSF is derived from S. epidermis.